Finally, an oral drug found effective
in treatment of Uterine Fibroids following successful phase-3 trial
Relugolix
successfully reduced heavy menstrual blood loss among Japanese women in a
Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to
Evaluate the Efficacy and Safety of Oral relugolix 40 mg as compared with injectable
leuprolide in the Treatment of Uterine Fibroids.
Relugolix is
an oral, once-daily, small molecule GnRH receptor antagonist that has been
evaluated in almost 1,600 study participants in Phase 1, Phase 2 and Phase 3
clinical trials. In these trials, it has shown to suppress estrogen and
progesterone levels in women and testosterone levels in men. (It is also being
evaluated in advanced prostate cancer via ongoing phase-3 HERO study).
Now ‘Switch’ the way you suture:
Reinventing suturing technique with the new device
Mellon Medical, a Dutch
MedTech developer has reinvented suturing by developing a device which
enables the surgeon to suture with only one hand, the other hand remaining free
to use as needed. The product is named Switch®, a single use precision
instrument that allows the surgeon to suture tubular structures or skin with
twice the speed of conventional suturing.
ACOG updates its guidelines on LARC
The American
College of Obstetricians and Gynecologists (ACOG) today updated its
guidelines on Long-Acting Reversible Contraception(LARC): Implants and
Intrauterine Devices. These updated guidelines were published online October 24 in Obstetrics &
Gynecology and replaces the old practice bulletin published in July 2011.
ACOG updates guidance on postpartum
hemorrhage- calls for standard, coordinated, protocol based intervention
The American
College of Obstetricians and Gynecologists (ACOG) recently released expanded
guidelines for management of postpartum hemorrhage (PPH)—the leading cause of
maternal mortality worldwide.
PPH is
defined as total blood loss of 1000 ml or more along with signs or symptoms of
hypovolemia within 24 hours after the labor, but can occur up to 12 weeks
postpartum. Although Maternal Mortality Rates(MMR) have decreased worldwide in
last 4 decades, it still accounts for 10% of all pregnancy related mortality.
Endometriosis fertility index can
accurately predict a women’s chances of conception after laparoscopy
The
Endometriosis fertility index can accurately predict the possibility of non-ART
conception or the need of ART for achieving pregnancy after surgical resection
of moderate-severe (Stage III–IV) endometriosis reports the results of
study published in Human Reproduction. The study confirmed
that adnexal function is deciding factor in evaluation of fertility prognosis
after the surgery.
There is no
evidence based guidelines about post-surgery fertility management of women who
have undergone surgery for severe endometriosis. Physicians differ in their
approach about the length of conservative treatment and that sometimes add
years and causes unnecessary delays.
